CN107406872B - 用于标记动物组织的化合物、组合物及其应用 - Google Patents

用于标记动物组织的化合物、组合物及其应用 Download PDF

Info

Publication number
CN107406872B
CN107406872B CN201680017762.XA CN201680017762A CN107406872B CN 107406872 B CN107406872 B CN 107406872B CN 201680017762 A CN201680017762 A CN 201680017762A CN 107406872 B CN107406872 B CN 107406872B
Authority
CN
China
Prior art keywords
compound
group
label
compounds
quencher
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680017762.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107406872A (zh
Inventor
马修·S·博焦
马蒂金·韦尔多斯
莱斯莉·奥弗里
尼马里·P·维索娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN107406872A publication Critical patent/CN107406872A/zh
Application granted granted Critical
Publication of CN107406872B publication Critical patent/CN107406872B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201680017762.XA 2015-01-22 2016-01-22 用于标记动物组织的化合物、组合物及其应用 Active CN107406872B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106400P 2015-01-22 2015-01-22
US62/106,400 2015-01-22
PCT/US2016/014606 WO2016118910A1 (en) 2015-01-22 2016-01-22 Protease-activated contrast agents for in vivo imaging

Publications (2)

Publication Number Publication Date
CN107406872A CN107406872A (zh) 2017-11-28
CN107406872B true CN107406872B (zh) 2023-03-28

Family

ID=56417841

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680017762.XA Active CN107406872B (zh) 2015-01-22 2016-01-22 用于标记动物组织的化合物、组合物及其应用

Country Status (6)

Country Link
US (3) US10570173B2 (enExample)
EP (1) EP3247802B1 (enExample)
JP (2) JP7017410B2 (enExample)
KR (1) KR102668593B1 (enExample)
CN (1) CN107406872B (enExample)
WO (1) WO2016118910A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用
GB201617935D0 (en) 2016-10-24 2016-12-07 Queens University Of Belfast The Binding compound and uses thereof
EP3510380B1 (en) 2016-12-23 2023-11-08 The Board of Trustees of the Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
EP3601261A4 (en) * 2017-03-30 2021-07-14 The Board of Trustees of the Leland Stanford Junior University CONTRAST AGENTS ACTIVATED BY A PROTEASE FOR IN VIVO IMAGING
US20220105206A1 (en) * 2020-10-02 2022-04-07 Board Of Regents, The University Of Texas System Sensitivity advances in ultrasound switchable fluorescence systems and techniques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743022A (zh) * 2007-05-16 2010-06-16 通用电气医疗集团股份有限公司 光学成像剂
CN102369440A (zh) * 2008-08-06 2012-03-07 得克萨斯A&M大学体系 细菌β-内酰胺酶在体外诊断与体内成像、诊断和治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60888A (en) * 1978-06-16 1984-07-31 Yeda Res & Dev Substrates and process for the quantitative assay of enzymes
AU2704395A (en) 1995-06-13 1997-01-09 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative di seases
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
US8133482B2 (en) * 2003-11-14 2012-03-13 The Trustees Of The University Of Pennsylvania Activatable photodynamic therapy agents
US20060148014A1 (en) * 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
US8968700B2 (en) 2005-08-11 2015-03-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging of protease activity in live cells using activity based probes
JP5437790B2 (ja) * 2006-04-28 2014-03-12 チルドレンズ ホスピタル メディカル センター 膜貫通薬物送達システムに適用するためのプロサポシン由来の融合タンパク質又はポリペプチドを含む組成物
CN101652149B (zh) * 2007-02-28 2012-11-14 塞诺菲-安万特股份有限公司 成像探针
MY162041A (en) 2007-02-28 2017-05-31 Sanofi Aventis Imaging probes
CA2695244A1 (en) * 2007-08-03 2009-02-12 Sanofi-Aventis Caspase imaging probes
WO2009124265A1 (en) 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
WO2010053489A1 (en) * 2008-11-07 2010-05-14 Children's Hospital Medical Center Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems
US9155471B2 (en) * 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
WO2012021800A2 (en) 2010-08-13 2012-02-16 Banyan Biomarkers Caspase inhibitors as therapeutics for neural and organ injury and imaging
WO2012118715A2 (en) 2011-02-28 2012-09-07 The Board Of Trustees Of Leland Stanford Junior University Non-peptidic quenched fluorescent imaging probes
US8709830B2 (en) * 2011-03-18 2014-04-29 Biotium, Inc. Fluorescent dyes, fluorescent dye kits, and methods of preparing labeled molecules
WO2013036743A1 (en) 2011-09-09 2013-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Imaging agents for imaging protease activity and uses thereof
US20140180073A1 (en) 2012-12-24 2014-06-26 Anticancer, Inc. Portable digital imaging system for fluorescence-guided surgery
KR20160037834A (ko) 2013-03-14 2016-04-06 루미셀, 아이엔씨. 의료 이미징 장치 및 사용 방법
WO2014145257A2 (en) * 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
WO2014171899A1 (en) * 2013-04-19 2014-10-23 Agency For Science, Technology And Research Tunable fluorescence using cleavable linkers
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用
EP3601261A4 (en) * 2017-03-30 2021-07-14 The Board of Trustees of the Leland Stanford Junior University CONTRAST AGENTS ACTIVATED BY A PROTEASE FOR IN VIVO IMAGING

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743022A (zh) * 2007-05-16 2010-06-16 通用电气医疗集团股份有限公司 光学成像剂
CN102369440A (zh) * 2008-08-06 2012-03-07 得克萨斯A&M大学体系 细菌β-内酰胺酶在体外诊断与体内成像、诊断和治疗中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
自制超声/荧光双功能造影剂在兔正常淋巴结中的显像;曲恩泽等;《中国医学科学院学报》;20130830;第35卷(第4期);第411-415页 *

Also Published As

Publication number Publication date
EP3247802A1 (en) 2017-11-29
WO2016118910A1 (en) 2016-07-28
JP2018511556A (ja) 2018-04-26
EP3247802B1 (en) 2024-08-28
US20200299327A1 (en) 2020-09-24
KR20180010177A (ko) 2018-01-30
EP3247802A4 (en) 2018-08-22
US10570173B2 (en) 2020-02-25
JP2022044770A (ja) 2022-03-17
US12459972B2 (en) 2025-11-04
US20240025945A1 (en) 2024-01-25
CN107406872A (zh) 2017-11-28
KR102668593B1 (ko) 2024-05-22
US20180002375A1 (en) 2018-01-04
JP7017410B2 (ja) 2022-02-08

Similar Documents

Publication Publication Date Title
US10829477B2 (en) Activity-based probe compounds, compositions, and methods of use
US12459972B2 (en) Protease-activated contrast agents for in vivo imaging
JP7720102B2 (ja) 活性ベースのプローブ化合物、組成物、および使用方法
US20240077475A1 (en) Protease-activated contrast agents for in vivo imaging

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment